Research Article - Biomedical Research (2017) Volume 28, Issue 18

Identification of mutations in cancer predisposition genes in radiosensitive and radioresistant patients with nasopharyngeal carcinoma

Xingwen Wang¹, Yunyan Wu², Qiang Li¹, Dongxiao Lv¹, Junqing Han^1* and Ping Liu^3*

¹Department of Tumor Research and Therapy Center, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, PR China

²Department of Ophthalmology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, PR China

³Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, PR China

*Corresponding Authors:

Junqing Han
Department of Tumor Research and Therapy Center
Shandong Provincial Hospital Affiliated to Shandong, University, PR China

 

Ping Liu
Department of Pharmacy
Shandong Provincial Hospital Affiliated to Shandong, University, PR China

 

Accepted on August 30, 2017

Abstract

The objective of the present study was to determine whether the alterations of cancer predisposition genes were different between radiosensitive and radioresistant patients with Nasopharyngeal Carcinoma (NPC). A total of 21 patients with nasopharyngeal carcinoma were included in this study. All patients were treated with standardized radiotherapy. Sixteen of the tumors were clinically radiosensitive and 5 were radioresistant. Genomic DNA, extracted from Formalin-Fixed Paraffin-Embedded (FFPE) tumor specimens obtained prior to treatment, was subjected to amplicon-based Next-Generation Sequencing (NGS) with primer sets targeting 50 critical human tumor suppressor genes and oncogenes. We identified 18 nonsynonymous mutations, 1 nonframeshift deletion and 1 frameshift mutation distributed across 15 genes, including 11 mutations have been reported in COSMIC (the Catalogue of Somatic Mutations in Cancer) or dbSNP database (database of single nucleotide polymorphisms), and 9 novel mutations. Most of these mutations have not been reported in NPC. More importantly, 5 radiosensitivespecific mutations targeting AKT1, PIK3CA, MET, TP53 and STK11 were observed, suggesting the genetic alterations of PI3K/AKT and p53 pathways were involved in the response to radiotherapy. Collectively, genetic mutations may differentiate tumor radiosensitivity and radioresistance, although validation of such mutations using a large sample size cohort is necessary before a solid conclusion can be reached.

Keywords

Mutations, Amplicon, Next-generation sequencing, Nasopharyngeal carcinoma.

Introduction

Nasopharyngeal Carcinoma (NPC) is extremely common in southern China, particularly in Guangdong, accounting for 18% of all cancers in China [1]. Epstein-Barr virus infection, heredity and environmental influences are major causes of NPC [2-4]. Most NPC patients are sensitive to radiotherapy, and combined radiochemotherapy may improve the survival of these patients [5,6]. However, radioresistance remains a serious problem affecting the treatment of NPC in many cases. If patients who tend to be resistant to radiotherapy can be identified before treatment and receive a higher dose of therapy without increased the rate of complications, the outcome of radiotherapy or combined radiochemotherapy may be significantly improved.

Microarrays and proteomics have been applied to identify radioresistance associated genes or proteins in multiple types of cancer, including NPC [7-15]. A number of studies have focused on the association between the radiosensitivity of various cancers and genetic changes of oncogenes and tumor suppressor genes, such as p53 [16-18], ATM (19), Epidermal Growth Factor Receptor (EGFR) [20,21]. Although mutations of RB2/p130 [22], p53 [23,24], PIK3CA [25-27] and EGFR [28] have been investigated in NPC, little is known about radioresistance-associated mutations in NPC.

With the advances in Next-Generation Sequencing (NGS) techniques, a large number of mutations have been identified in cancers [29]. Multiplex amplicon-based NGS, sequencing only the Regions of Interest (ROI), has several advantages: requires relatively small amounts of DNA, is relatively low cost and is compatible with Formalin-Fixed Paraffin-Embedded (FFPE)- DNA [30]. In the current study, genomic DNA was extracted from FFPE tissue samples from radiosensitive and radioresistant patients with NPC, and then the hotspot regions of 50 critical human tumor suppressor genes and oncogenes were amplified. Amplicon-based NGS was carried out to investigate any potential correlation of mutational hot spots with radiosensitivity.

Materials and Methods

Collection of NPC specimens

A total of 21 Formalin-Fixed Paraffin-Embedded (FFPE) samples were taken form Shandong Provincial Hospital Affiliated to Shandong University, China after approval by the local ethics committee. All patients were given written informed content. All patients were treated with two cycles of radiotherapy (50-70 Gy total dose) after cisplatin-docetaxel induction chemotherapy. Four response categories are proposed: complete response (CR, which means the disappearance of all detectable tumor), partial response (PR, which is defined as more than 50% decrease in tumor size), stable disease (SD, which means tumor remains the same size), and Progressive Disease (PD). Radiosensitive patients are those reached CR 2 to 4 w after completion of radiotherapy, and radioresistant patients are clarified as those of PR or SD or even with PD 2 to 4 w after completion of radiotherapy. FFPE specimens were obtained prior to treatment, and 16 patients were found radiosensitive (Samples 1-16) and 5 patients (Samples 17-21) were found radioresistant during follow-up.

DNA isolation and amplicon library preparation

Genomic DNA was extracted separately from FFPE samples using QIAamp DNA FFPE Tissue Kit (QIAGEN, Hilden, Germany) according to the manufacturer’s protocol. The concentrations of isolated FFPE-DNA samples were determined on a Qubit 2.0 Fluorometer (Life Technologies).

The amplicon library was prepared using DNA Seq Library Preparation Kit for Amplicon Sequencing-Illumina Compatible (Gnomegen, San Diego, CA), which contains 207 primer pairs and targets 50 proto-oncogenes and tumor suppressor genes (Table 1). Target sequences were amplified with 10 ng FEPEDNA. Subsequently, end repair, barcode ligation and a simple PCR amplification were performed following the manufacturer’s instructions with several purification steps (Gnomegen). The barcode sequences were unique for each sample. Size selection was then performed to obtain clean library products. Following Quality Control, 21 purified and quantified libraries were pooled to form a library product.

Table 1. The panel of 50 proto-oncogenes and tumor suppressor genes.

Illumina sequencing and sequence assembly

Sequencing was performed on an Illumina Hiseq2000 sequencing platform (Illumina, San Diego, CA) with 150 bp pair reads. After sequencing, the raw data were separately trimmed to remove 5’- and 3’- adapters and low quality regions (<Q20). After discarding reads shorter than 50 bp, reads were mapped against a reference genome using Burrows-Wheeler Alignment tool (BWA). Variances were identified by VarScan software (http://varscan.sourceforge.net) with the following parameters: minimum base quality of 20, minimum coverage of 30X, minimum variation frequency of 3%, no strand bias, and a P value of less than 0.05.

Results

Sequencing data

We applied NGS to investigate mutations of 50 protooncogenes and tumor suppressor genes on 5 radioresistant (Samples 17-21) and 16 radiosensitive (Samples 1-16) patients. We generated 1.3-2.4 million sequencing reads per sample (Q20>96% and Q30>93%). As shown in Table 2, the align rate was >98%, on target rate was >93%, the average read depth (the number of times a nucleotide is sequenced) per sample was 5000X, and coverage uniformity was >90%. Thus, the sequencing data allowed the detection of variances.

Table 2. Quality control of sequencing data.

Frequency and distribution of variances

After data processing, 67 variances were detected in the 21 samples (Table S1). Then, we excluded 27 variances within Untranslated Region (UTR) and intron, as well as 20 synonymous mutations (no amino acid change occurred), and obtained 20 distinct variants (18 nonsynonymous, 1 nonframeshift deletion and 1 frameshift) of 15 genes (PTEN, HRAS, AKT1, IDH2, CDH1, TP53, SMAD4, STK11, PIK3CA, FGFR3, KDR, APC, MET, FGFR1 and NOTCH1) (Table 3). Of the 20 distinct variants, 10 were found in COSMIC database (the Catalogue of Somatic Mutations in Cancer) [31] and 8 variants were found in dbSNP database (database of single nucleotide polymorphisms) [32]. Nine novel variants, which were not found in COSMIC database or dbSNP, were then subjected to Polyphen2 (http://genetics.bwh.harvard.edu/ pph2/). The results showed that 8 novel variants were predicted to be “probably damaging” or “possibly damaging”.

Screening for radioresistance-associated variances

By comparing the 20 variances occurred in radiosensitive and radioresistant samples, we found that 5 variants occurred only in radiosensitive samples, but not in radioresistant samples. These 5 variants may be associated with radioresistance (Table 3). No obvious difference was observed in other 15 variants between the two groups of samples. Table 1.

Table 3. Identified distinct variants.

Discussion

Radioresistance remains a major obstacle to the treatment of NPC. Genetic changes have been reported to be associated with the radiosensitivity of various cancers. Identification of NPC radioresistance-associated mutations will help finding biomarkers to predict the response to radiotherapy and explaining the molecular mechanisms of NPC radioresistance. As far as we known, this study represents the first sequencing study of multiple oncogenes and tumor suppresser genes in radiosensitive and radiotolerant NPC patients.

In this study, NPC samples were tested with a 50-gene hotspot panel, of which, mutations in PIK3CA, NRAS, KIT, PDGFRA, ABL, HRAS, BRAF and EGFR [24,26-28,33,34] have been reported in NPC. Here, we identified 18 nonsynonymous mutations, 1 nonframeshift deletion and 1 frameshift mutation distributed across 15 oncogenes and tumor suppresser genes, of which 8 mutations were previously observed in dbSNP and 10 mutations, were already known Cancer-Associated Mutations (COSMIC). By analyzing with Polyphen-2 Software, 8 of the 9 novel mutations were predicted to be damaging. These results suggested that we have identified novel mutations which may be associated with tumorigenesis. Alterations in most of the 15 genes have not been reported in NPC, except PI3CA and TP53. Our study also provided novel information regarding gene alterations during NPC tumorigenesis.

The PI3K/AKT pathway is known to regulating radioresistance in cancer cells [35-37] and experimental animals [38]. p53 is a well-known regulator of radiosensitivity in tumor cells [39,40]. By comparing radioresistant and radiosensitive samples, 5 radiosensitive-specific mutations, AKT1 (COSM33765), PIK3CA (COSM27497, COSM342716), MET (COSM710), TP53 (COSM131026, COSM131025 and COSM131024) and STK11 (COSM21360), were identified, suggesting the genetic alterations of PI3K/AKT and p53 pathways were involved in the response to radiotherapy. However, these mutations should be validated by large sample size cohort. In vitro and in vivo experiments with these mutations may further elucidate the underlying mechanisms.

In summary, the present study has identified several candidate variants in NPC patients that may be used to predict increased radiosensitivity although the sample size was relatively small. Our findings reported may be used to distinguish radiosensitive and radioresistant patients before treatment, thus driving personalized therapeutic strategies and improving the therapy outcome.

Acknowledgements

This work was supported by the grant from the Science and Technology Development Plan Project of Shandong Province (No. 2012G0021822).

Competing Interests

No conflict of interest to declare.

References

1. Fang W, Li X, Jiang Q, Liu Z, Yang H, Wang S. Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of Southern China. J Translat Med 2008; 6: 32.
2. Armstrong RW, Armstrong MJ, Mimi CY, Henderson BE. Salted fish and inhalants as risk factors for nasopharyngeal carcinoma in Malaysian Chinese. Cancer Res 1983; 43: 2967-2970.
3. Henderson BE, Louie E, Jing JS, Buell P, Gardner MB. Risk factors associated with nasopharyngeal carcinoma. N Engl J Med 1976; 295: 1101-1106.
4. Chen C, Liang KY, Chang Y, Wang Y, Hsieh T, Hsu M. Multiple risk factors of nasopharyngeal carcinoma: Epstein-Barr virus, malarial infection, cigarette smoking and familial tendency. Anticancer Res 1989; 10: 547-553.
5. DeNittis AS, Liu L, Rosenthal DI, Machtay M. Nasopharyngeal carcinoma treated with external radiotherapy, brachytherapy, and concurrent/adjuvant chemotherapy. Am J Clin Oncol 2002; 25: 93-95.
6. Teo P, Yu P, Lee W, Leung S, Kwan W, Yu K. Significant prognosticators after primary radiotherapy in 903 nondisseminated nasopharyngeal carcinoma evaluated by computer tomography. Int J Rad Oncol Biol Phys 1996; 36: 291-304.
7. Wong YF, Sahota DS, Cheung TH, Lo KW, Yim SF, Chung TK. Gene expression pattern associated with radiotherapy sensitivity in cervical cancer. Cancer J (Sudbury, Mass) 2006; 12: 189-193.
8. Ogawa K, Utsunomiya T, Mimori K, Tanaka F, Haraguchi N, Inoue H. Differential gene expression profiles of radioresistant pancreatic cancer cell lines established by fractionated irradiation. Int J Oncol 2006; 28: 705-713.
9. Uzawa MK, Bukawa YKH, Nimura Y, Seki N, Tanzawa H. Identification of candidate radioresistant genes in human squamous cell carcinoma cells through gene expression analysis using DNA microarrays. Oncol Rep 2005; 14: 1293-1298.
10. Guo WF, Lin RX, Huang J, Zhou Z, Yang J, Guo GZ. Identification of differentially expressed genes contributing to radioresistance in lung cancer cells using microarray analysis. Rad Res 2005; 164: 27-35.
11. Fukuda K, Sakakura C, Miyagawa K, Kuriu Y, Kin S, Nakase Y. Differential gene expression profiles of radioresistant oesophageal cancer cell lines established by continuous fractionated irradiation. Br J Cancer 2004; 91: 1543-1550.
12. Chang JTC, Chan SH, Lin CY, Lin TY, Wang HM, Liao CT. Differentially expressed genes in radioresistant nasopharyngeal cancer cells: gp96 and GDF15. Mol Cancer Ther 2007; 6: 2271-2279.
13. Feng XP, Yi H, Li MY, Li XH, Yi B, Zhang PF. Identification of biomarkers for predicting nasopharyngeal carcinoma response to radiotherapy by proteomics. Cancer Res 2010; 70: 3450-3462.
14. Lin TY, Chang JTC, Wang HM, Chan SH, Chiu CC, Lin CY. Proteomics of the radioresistant phenotype in head-and-neck cancer: Gp96 as a novel prediction marker and sensitizing target for radiotherapy. Int J Rad Oncol Biol Phys 2010; 78: 246-256.
15. Skvortsova I, Skvortsov S, Stasyk T, Raju U, Popper BA, Schiestl B. Intracellular signaling pathways regulating radioresistance of human prostate carcinoma cells. Proteomics 2008; 8: 4521-4533.
16. Servomaa K, Kiuru A, Grenman R, Pekkola‐Heino K, Pulkkinen J, Rytomaa T. p53 mutations associated with increased sensitivity to ionizing radiation in human head and neck cancer cell lines. Cell Proliferat 1996; 29: 219-230.
17. Jung M, Notario V, Dritschilo A. Mutations in the p53 gene in radiation-sensitive and-resistant human squamous carcinoma cells. Cancer Res 1992; 52: 6390-6393.
18. Hamada M, Fujiwara T, Hizuta A, Gochi A, Naomoto Y, Takakura N. Thep53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers. J Cancer Res Clin Oncol 1996; 122: 360-365.
19. Chenevix-Trench G, Spurdle AB, Gatei M, Kelly H, Marsh A, Chen X. Dominant negative ATM mutations in breast cancer families. J Nat Cancer Inst 2002; 94: 205-215.
20. Das AK, Sato M, Story MD, Peyton M, Graves R, Redpath S. Non-small cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. Cancer Res 2006; 66: 9601-9608.
21. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
22. Claudio PP, Howard CM, Fu Y, Cinti C, Califano L, Micheli P. Mutations in the retinoblastoma-related gene RB2/p130 in primary nasopharyngeal carcinoma. Cancer Res 2000; 60: 8-12.
23. Spruck CH, Tsai YC, Huang DP, Yang AS, Rideout WM, Gonzalez-Zulueta M. Absence of p53 gene mutations in primary nasopharyngeal carcinomas. Cancer Res 1992; 52: 4787-4790.
24. Effert P, McCoy R, Abdel-Hamid M, Flynn K, Zhang Q, Busson P. Alterations of the p53 gene in nasopharyngeal carcinoma. J Virol 1992; 66: 3768-3675.
25. Or YYY, Hui ABY, To KF, Lam CNY, Lo KW. PIK3CA mutations in nasopharyngeal carcinoma. Int J Cancer 2006; 118: 1065-1067.
26. Chou CC, Chou MJ, Tzen CY. PIK3CA mutation occurs in nasopharyngeal carcinoma but does not significantly influence the disease-specific survival. Med Oncol (Northwood, London, England) 2009; 26: 322-326.
27. Fendri A, Khabir A, Mnejja W, Sellami-Boudawara T, Daoud J, Frikha M. PIK3CA amplification is predictive of poor prognosis in Tunisian patients with nasopharyngeal carcinoma. Cancer Sci 2009; 100: 2034-2039.
28. Naji F, Attaleb M, Laantri N, Benchakroun N, El Gueddari B, Benider A. Identification of G2607A mutation in EGFR gene with a significative rate in Moroccan patients with nasopharyngeal carcinoma. Cell Mol Biol (Noisy-le-Grand, France) 2010; 56: 1442-1446.
29. Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Gene 2010; 11: 685-696.
30. Chang F, Li MM. Clinical application of amplicon-based next-generation sequencing in cancer. Cancer Gene 2013; 206: 413-419.
31. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H. COSMIC: exploring the worlds knowledge of somatic mutations in human cancer. Nucl Acids Res 2015; 43: 805-811.
32. Sherry ST, Ward M-H, Kholodov M, Baker J, Phan L, Smigielski EM. dbSNP: the NCBI database of genetic variation. Nucl Acids Res 2001; 29: 308-311.
33. Zhang ZC, Fu S, Wang F, Wang HY, Zeng YX, Shao JY. Oncogene mutational profile in nasopharyngeal carcinoma. OncoTargets Ther 2014; 7: 457.
34. Huang PY, Hong MH, Zhang X, Mai HQ, Luo DH, Zhang L. C-KIT overexpression and mutation in nasopharyngeal carcinoma cell lines and reactivity of imatinib on these cell lines. Chinese J Cancer 2010; 29: 131-135.
35. Kim IA, Bae SS, Fernandes A, Wu J, Muschel RJ, McKenna WG. Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines. Cancer Res 2005; 65: 7902-7910.
36. Ni J, Cozzi P, Hao J, Beretov J, Chang L, Duan W. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway. Int J Biochem Cell Biol 2013; 45: 2736-2748.
37. Chang L, Graham P, Hao J, Ni J, Bucci J, Cozzi P. PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways. Cell Death Dis 2014; 5: 1437.
38. Fokas E, Im JH, Hill S, Yameen S, Stratford M, Beech J. Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature. Cancer Res 2012; 72: 239-248.
39. El-Deiry WS. The role of p53 in chemosensitivity and radiosensitivity. Oncogene 2003; 22: 7486-7495.
40. Bohnke A, Westphal F, Schmidt A, El‐Awady R, Dahm‐Daphi J. Role of p53 mutations, protein function and DNA damage for the radiosensitivity of human tumour cells. Int J Rad Biol 2004; 80: 53-63.